News

 [Taipei, June 28, 2024] 

PharmaEssentia today released its 5th "2023 ESG Sustainability Report". The report details the significant ESG advancements, performance indicators, and future vision toward sustainability over the past five years, showcasing its commitment to Authentic and Eternal Value Creating. Since 2019, we have aligned corporate social responsibility into our core business strategy, progressing from Initial ESG Planning and Assessment, Execution and Adjustments, Performance Demonstration, and Results Communication, to achieving a Sustainability Leap in 2023, thus completing our first phase of Five-Year Sustainability Blueprint.   

This year, PharmaEssentia was honored to be selected as one of the top 10 global biotech companies in the S&P Global Corporate Sustainability Assessment (CSA) and included in the S&P Global The Sustainability Yearbook 2024. As the first and only representative from Taiwan's biotech industry, especially in our final year of our initial five-year sustainability blueprint, we deeply appreciate the sincere recognition and high praise from S&P Global CSA , the world's most prestigious sustainability assessment organization. This achievement not only validates our commitment to the right path but also inspires us to continue steadfastly promoting more impactful and sustainable development strategies in the future.  

In addition, in 2023 PharmaEssentia continued to achieve multiple accolades, including the 16th Taiwan Corporate Sustainability Awards (TCSA) Platinum Award in the healthcare sector and the 6th Global Corporate Sustainability Awards (GCSA) Bronze Award. Moreover, for the first time, our sustainability initiatives at the MPN Asia Medical Annual Meeting earned us the APSAA Asia Pacific Sustainability Action Silver Award and the TSAA Taiwan Sustainability Action Bronze Award.   

Verified and validated by the 3rd party to ensure the accuracy and reliability of our sustainability reporting. 

We proactively referenced various international sustainability guidelines and biotech industry standards in compiling the report, including adopting the Global Reporting Initiative (GRI) Standards 2021, AA1000 Accountability, the United Nations Global Compact, Sustainable Development Goals (SDGs), SASB Biotech Industry Standards, TCFD, and the Access to Medicine Index 2024 frameworks.  

We are committed to sustainable development, firmly believing that businesses have a responsibility not only to pursue profits but also to environmental, social, and corporate governance. In terms of (E) climate action, we actively address the 2050 net-zero emissions and 2030 industry-wide carbon reduction goals, promoting the ISO 14001 environmental management system to minimize environmental impact during production, and continuously enhancing the TCFD guidance framework to strengthen environmental protection efforts. In (S) social inclusion, we continuously invest in R&D for new drugs to meet unmet medical needs, adhere to the ATMI drug proximity guidelines, and collaborate with subsidiaries and partners to promote Access To Medicine /Healthcare initiatives. In (G) corporate governance, we adhere to integrity in operations, continuously improve risk assessment and process management, accelerate global market expansion, enhance global brand value, and consolidate market position and reputation.   

In 2023, a total of 46 ESG highlights underscored achievements in governance, pharmaceutical quality and safety management, employee well-being culture, social contributions, and sustainable environmental efforts. 

In terms of governance, the company strictly adhered to ethical standards with no compliance issues and actively promoted gender diversity, achieving 100% attendance by boards and compensation committees. Regarding pharmaceutical quality and safety management, the company invested heavily in R&D and ensured comprehensive drug safety monitoring training for new employees. In fostering an employee well-being culture, the company implemented policies of equality and fairness, conducted extensive safety education training, and received high ratings for its lactation room facilities. In social contributions, the company launched multiple health education platforms, assisted in establishing treatment centers, supported public welfare initiatives, and participated in carbon reduction projects. In sustainable environmental practices, the company actively promoted sustainability reporting and achieved significant results in greenhouse gas reduction, energy efficiency, and water resource recycling, demonstrating its commitment to environmental sustainability.   

For more information About PharmaEssentia's 2023 ESG Sustainability Report : You can download the report on PharmaEssentia's ESG portal http://www.pharmaessentia-esg.com  

Contact PharmaEssentia's Sustainable Development Center:   Phone: +886.2 26557688       Email: CSR-ESG@pharmaessentia.com   

Disclaimer: This information is for reference only and may not fully describe the complete operations of the company. Any forward-looking statements do not guarantee future governance levels, operational performance, or financial health of the company.